Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck 2Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck

2Q Revenues: $6.1 billion (-1%)

2Q Earnings: $1.8 billion (+5%)

YTD Revenues: $11.9 billion (flat)

YTD Earnings: $5.1 billion (+50%)

Comments: Worldwide sales of Singulair were $1.1 billion in the quarter (-1%). Combined worldwide sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough joint venture, were $1.2 billion (-9%). Worldwide sales of Zetia, marketed as Ezetrol outside the U.S., were $560 million (-3%). Worldwide sales of Vytorin, marketed outside the U.S. as Inegy, were $592 million (-14%). Cozaar and Hyzaar sales were $941 million (+11%). Sales of Fosamax and Fosamax Plus D, marketed as Fosavance in the EU, were $411 million (–48%) due to loss of U.S. marketing exclusivity. Sales Januvia, Janumet and Isentress were $2.0 billion in the quarter (+24%). Worldwide vaccine sales were $995 million (-5%). R&D expenses were $1.2 billion for the quarter (+13%). Restructuring costs, primarily representing employee separation costs associated with the company’s global restructuring program, were $102 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters